IL310243A - 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORHOLIN-4-YL-1,3,5-TRIAZIN-2-YL )PHENYL]urea (GEDATOLISIB) and its combinations for use in cancer treatment - Google Patents
1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORHOLIN-4-YL-1,3,5-TRIAZIN-2-YL )PHENYL]urea (GEDATOLISIB) and its combinations for use in cancer treatmentInfo
- Publication number
- IL310243A IL310243A IL310243A IL31024324A IL310243A IL 310243 A IL310243 A IL 310243A IL 310243 A IL310243 A IL 310243A IL 31024324 A IL31024324 A IL 31024324A IL 310243 A IL310243 A IL 310243A
- Authority
- IL
- Israel
- Prior art keywords
- phenyl
- dimorpholin
- gedatolisib
- triazin
- piperidin
- Prior art date
Links
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229950008209 gedatolisib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225707P | 2021-07-26 | 2021-07-26 | |
| US202163285327P | 2021-12-02 | 2021-12-02 | |
| PCT/US2022/038188 WO2023009438A1 (en) | 2021-07-26 | 2022-07-25 | 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310243A true IL310243A (en) | 2024-03-01 |
Family
ID=82932627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310243A IL310243A (en) | 2021-07-26 | 2022-07-25 | 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORHOLIN-4-YL-1,3,5-TRIAZIN-2-YL )PHENYL]urea (GEDATOLISIB) and its combinations for use in cancer treatment |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12350276B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4376848A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024529430A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240040768A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022320615B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3227191A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024000208A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310243A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024001266A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202320795A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023009438A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025049962A1 (en) * | 2023-08-31 | 2025-03-06 | Aadi Bioscience, Inc. | Combination cancer treatments with a composition comprising an mtor pathway inhibitor |
| US20260053814A1 (en) * | 2024-08-21 | 2026-02-26 | Celcuity Inc. | Treatment regimens for gedatolisib in hormonally-driven disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| NZ534069A (en) | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| JP5190271B2 (ja) | 2005-01-14 | 2013-04-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤としての5員の環付加複素環式ピリミジン |
| US10022381B2 (en) | 2008-05-23 | 2018-07-17 | Pfizer Inc. | Triazine compounds as PI3 kinase and mTOR inhibitors |
| MY155653A (en) | 2008-05-23 | 2015-11-13 | Wyeth Llc | Triazine compounds as p13 kinase and mtor inhibitors |
| AU2009284098B2 (en) | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| KR102186969B1 (ko) | 2010-10-25 | 2020-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| EP2791132A4 (en) | 2011-12-14 | 2015-08-05 | Seragon Pharmaceuticals Inc | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
| BR112015030595A2 (pt) | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
| EP3116547B1 (en) | 2014-03-14 | 2019-06-05 | Pfizer Inc | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| HUE055928T2 (hu) | 2014-12-17 | 2022-01-28 | Pfizer | PI3K/MTOR-inhibitorok készítményei intravénás adagolásra |
| LT3672571T (lt) | 2017-08-25 | 2021-12-10 | Pfizer Inc. | Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą |
| US12109308B2 (en) | 2018-06-07 | 2024-10-08 | Pfizer Inc. | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yljcarbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| EP3863618A1 (en) * | 2018-10-08 | 2021-08-18 | F. Hoffmann-La Roche AG | Methods of treating cancer with pi3k alpha inhibitors and metformin |
-
2022
- 2022-07-25 KR KR1020247005862A patent/KR20240040768A/ko active Pending
- 2022-07-25 TW TW111127690A patent/TW202320795A/zh unknown
- 2022-07-25 WO PCT/US2022/038188 patent/WO2023009438A1/en not_active Ceased
- 2022-07-25 US US17/872,721 patent/US12350276B2/en active Active
- 2022-07-25 MX MX2024001266A patent/MX2024001266A/es unknown
- 2022-07-25 EP EP22754997.9A patent/EP4376848A1/en active Pending
- 2022-07-25 AU AU2022320615A patent/AU2022320615B2/en active Active
- 2022-07-25 JP JP2024504503A patent/JP2024529430A/ja active Pending
- 2022-07-25 IL IL310243A patent/IL310243A/en unknown
- 2022-07-25 CA CA3227191A patent/CA3227191A1/en active Pending
-
2024
- 2024-01-24 CL CL2024000208A patent/CL2024000208A1/es unknown
-
2025
- 2025-06-05 US US19/229,722 patent/US20250345342A1/en active Pending
- 2025-08-27 AU AU2025223785A patent/AU2025223785A1/en active Pending
-
2026
- 2026-02-13 US US19/539,411 patent/US20260174772A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022320615B2 (en) | 2025-08-21 |
| US20260174772A1 (en) | 2026-06-25 |
| CL2024000208A1 (es) | 2024-07-19 |
| KR20240040768A (ko) | 2024-03-28 |
| EP4376848A1 (en) | 2024-06-05 |
| AU2022320615A1 (en) | 2024-03-14 |
| JP2024529430A (ja) | 2024-08-06 |
| TW202320795A (zh) | 2023-06-01 |
| US20230022525A1 (en) | 2023-01-26 |
| CA3227191A1 (en) | 2023-02-02 |
| WO2023009438A1 (en) | 2023-02-02 |
| US20250345342A1 (en) | 2025-11-13 |
| US12350276B2 (en) | 2025-07-08 |
| MX2024001266A (es) | 2024-04-16 |
| AU2025223785A1 (en) | 2025-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005012241A3 (en) | p-38 KINASE INHIBITORS | |
| WO2007064872A3 (en) | Urea compounds useful in the treatment of cancer | |
| IL180137A0 (en) | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer | |
| IL189194A (en) | Benzimidazoles are conserved as kinase inhibitors and their use in the preparation of cancer drugs | |
| IL183108A (en) | Triazole Compounds, Containing and Using Pharmaceutical Preparations for the Treatment of Prosperity Irregularities | |
| WO2005094376A3 (en) | Synergistic methods and compositions for treating cancer | |
| NZ611314A (en) | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | |
| GEAP202215447A (en) | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
| ATE526987T1 (de) | Dr5-antikörper und deren verwendung | |
| NZ600716A (en) | Substituted isoquinolinones and quinazolinones | |
| AP2006003621A0 (en) | Methods for treatment modification and management of pains using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoin-doleline | |
| WO2007059202A3 (en) | Pyrazolyl urea derivatives useful in the treatment of cancer | |
| IL279270A (en) | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | |
| SI3658147T1 (sl) | Kombinacija, ki vsebuje palbociklib in 6-(2,4-diklorofenil)-5-(4-((3S)- 1-(3-fluoropropil)pirolidin-3-il)oksifenil)-8,9-dihidro-7H-benzo(7) anulen-2-karboksilno kislino in njena uporaba za zdravljenje raka | |
| EP1940456A4 (en) | WWOX GENE, VECTORS COMPRISING THE SAME, AND USES THEREOF IN THE TREATMENT OF CANCER | |
| NZ594556A (en) | Carboxamide compounds and methods for using the same | |
| IL180138A0 (en) | 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer | |
| MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
| PL3672571T3 (pl) | Wodna farmaceutyczna postać użytkowa zawierająca 1-(4-{[4-(dimetyloamino)piperydyn-1-ylo]karbonylo}fenylo)-3-[4-(4,6-dimorfolin-4-ylo-1,3,5-triazyn)-2-ylo)fenylo]mocznik | |
| PT1921077T (pt) | Agente para tratar e/ou prevenir distúrbio do sono | |
| WO2004092144A3 (en) | Quinazoline compounds useful as p38 kinase inhibitors | |
| MX2012014386A (es) | Formas cristalinas de inhibidores de cinasa. | |
| IL320871A (en) | Dnase 1-like 3 engineered for improved expression and therapeutic use | |
| HK40107025A (en) | 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer | |
| TW200745088A (en) | Benzimidazoles useful as inhibitors of protein kinases |